Category Archives: Glucose Monitoring

Lilly Orfor Obesity/ORC Prevention Study; NewAmsterdam Alzheimer’s Study; Novartis to Advance IL-6 Inhibitor to Ph3; Wegovy Pill Germany Launch; Pfizer Berobenatide Japan Studies; MiniMed CY Q2 ’26 Earnings; Novo Initiates AMBITION 7

A series of cardiometabolic-related news items has been observed from Lilly, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, MiniMed, and CSPC Pharmaceutical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Abbott’s Libre Duo Approved by FDA; AZ Initiates Pivotal Amylin Studies; New Lilly Medicare Obesity Ad; Lilly Initiates First Clazakizumab Study; Google Pixel Watch Non-Invasive Insulin Resistance; Revier Seed Financing for HFpEF and ASCVD; Haisco Partners with US-Based VC for Spinout

A series of cardiometabolic-related news items has been observed from Abbott, AstraZeneca, Lilly, Google, Revier Therapeutics, and Haisco Pharmaceutical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo New Ph1 AOM; MiniMed Flex with Instinct CGM Now Available in US; Arrowhead Launches Redemplo in Germany; Sandoz Partners for Biosimilars; Baxfendy Misses ICER Mark

A series of cardiometabolic-related news items has been observed from Novo Nordisk, MiniMed, Arrowhead Pharmaceuticals, Sandoz/Henlius, and AstraZeneca. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Awiqli US Launch; AZ Ph3 Eleco CKD Study; BI Ph3 Survo T2DM Study; Abbott + Google Glucose Partnership

A series of cardiometabolic-related news items has been observed from Novo Nordisk, AstraZeneca, Boehringer Ingelheim, and Abbott/Google. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Structure, Senseonics, Tandem, and Biocon Q2 ’26 Earnings

A series of cardiometabolic-related news items has been observed from Structure Therapeutics, Senseonics, Tandem Diabetes Care, and Biocon. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Dexcom Q2 ’26 Earnings; Novo Ziltivekimab CVOT Miss; CSPC Initiates China-Based QM Dual Agonist Study

Three cardiometabolic-related news items have been observed: Dexcom hosted its Q2 ’26 earnings call (view press release; view slides); Novo’s Ph3 ZEUS trial evaluating ziltivekimab missed the primary CV endpoint (view press release); and CSPC initiated a Ph1 study evaluating its QM GLP-1/GIP dual agonist (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Roche Q2 ’26 Earnings; New Retatrutide Ph3 Data; Trinity Biotech Partners with Latch Medical; Dexcom Joins FDA TEMPO Pilot Program

A series of cardiometabolic-related news items has been observed from Roche, Lilly, Trinity Biotech, and Dexcom. Below, FENIX provides highlights and insights for the respective news items, including insight into Lilly’s retatrutide regulatory strategy.

This content is for Read Less members only.

Already a member? Log in here

Novo Sues Lilly Over DTC Ads; Novartis Q2 ’26 Earnings; Aspen Generic Sema in Canada; Medtrum 300U Patch Pump to Launch in Germany; Hilo Launches Cuffless BP Monitor in US

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Novartis, Aspen Pharmacare, Medtrum, and Hilo. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Merck’s Oral PCSK9i Approved by FDA; BI Ph2 Triple Agonist Study; Abbott Q2 ’26 Earnings; Syntis Ph1 Obesity Data; Lilly Invests in Oura; Braveheart IPO

A series of cardiometabolic-related news items has been observed from Merck, Boehringer Ingelheim, Abbott, Syntis Bio, Oura/Lilly, and Braveheart. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

D&D and Pfizer Expand Research Agreement; Dexcom G7 15-Day Health Canada Clearance; Insulet Partners with Calm

Three cardiometabolic-related news items have been observed: D&D Pharmatech extended its oral obesity research agreement with Pfizer (view article), Dexcom received clearance of its G7 15-Day CGM in Canada (view press release), and Insulet partnered with Calm to provide well-being resources for diabetes management (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here